Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agent

Cancer and Metastasis Reviews

Volumn 12, Issue 2, 1993, Pages 119-134

  Patterson, Laurence H ^a  

^a DE MONTFORT UNIVERSITY   (United Kingdom)

Author keywords

bisalkylaminoanthraquinone; cytochrome P450; haemoproteins; hypoxia; in vivo activity; prodrug

Indexed keywords

1,4 BIS[[2 (DIMETHYLAMINO N OXIDE)ETHYL]AMINO] 5,8 DIHYDROXYANTHRAQUINONE; ANTHRAQUINONE DERIVATIVE; AQ 4 N; DNA; DNA POLYMERASE; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); MITOXANTRONE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE FERRIHEMOPROTEIN REDUCTASE; RNA POLYMERASE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BINDING AFFINITY; DNA BINDING; DRUG DNA BINDING; DRUG METABOLISM; DRUG POTENCY; DRUG STRUCTURE; ENZYME INHIBITION; HYPOXIA; OXIDATION REDUCTION REACTION; OXYGEN TISSUE LEVEL; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMAL; ANTHRAQUINONES; ANTINEOPLASTIC AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; CYTOTOXINS; DNA; DRUG DESIGN; HUMAN; NEOPLASMS; OXIDATION-REDUCTION; PRODRUGS; SUPPORT, NON-U.S. GOV'T;

EID: 0027220811     PISSN: 01677659     EISSN: 15737233     Source Type: Journal    
DOI: 10.1007/BF00689805     Document Type: Article

References (94)

1. Sensitization of hypoxic tumour cells - clinical experience
2. Non-invasive assessment of human tumour hypoxia with123I-iodazomycin arabinoside: preliminary report of a clinical study
3. Tumour hypoxia, reoxygenation and oxygenation strategies: possible role in photodynamic therapy
4. Hypoxic fractions of human tumors xenografted into mice: a review
5. Hypoxic fractions of solid tumors: experimental techniques, methods of analysis, and a survey of existing data
6. Localisation of tumors and evolution of their state of oxygenation by phosphorescence imaging
7. Regional blood flow in human tumors
8. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumours. A review
9. Reductive drug metabolism
10. DT-Diaphorase and cancer chemotherapy
11. The toxicity of nitro compounds towards hypoxic mammalian cells in vitro: dependence upon reduction potential
12. Keynote address: bioreductive mechanisms
13. Indicine N-oxide: clinical use of a pyrollizidine alkaloid
14. Synthesis of pyrollizidine alkaloids indicine, intermedine, lycopsamine and analogues and their N-oxides. Potential antitumor agents
15. Semisynthetic pyrrollizidine alkaloid N-oxide antitumor agents. Esters of Heliotridine
16. Metabolism of SR4233 by chinese hamster ovary cells: basis of selective hypoxic cytotoxicity
17. Microsomal reduction of 3-amino-1,2,4-benzotriazine 1,4-dioxide to a free radical
18. The role of cytochrome P450 and cytochrome P450 reductase in the reductive bioactivation of the novel benzotriazine di-N-oxide hypoxic cytotoxin SR4233 (WIN 59075) by mouse liver
19. Enzymology of the reduction of the potent benzotriazine-di-N-oxide hypoxic cell cytotoxin SR 4233 (WIN 59075) by NAD(P)H:(quinone acceptor) oxidoreductase (EC 1.6.99.2) purified from Walker 256 rat tumour cells
20. Alkylating prodrugs in cancer chemotherapy
21. Cahill A, White INH: Reductive cleavage of N-oxides to cause strand breakage in cell lines in vitro. Biochem Soc Trans 19: 127S, 1991
22. Synthesis and anticancer activity of cytosine arabinoside 3-N-Oxide
23. Toxicity and metabolism of 3′deoxyribosine N1-oxide in mice and Ehrlich ascites tumor cells
24. Analgues of Tamoxifen: the role of the basic side-chain. Applications of a whole cell oestrogen-receptor binding assay to N-oxides and quarternary salts
25. The pharmacology and biochemistry of N-oxides
26. Liver metabolic reactions: Tertiary amine N-dealkylation, tertiary amine N-oxidation, N-oxide reduction and N-oxide N-dealkylation. I. Tricyclic tertiary amine drugs
27. The metabolism of chlorpromazine by liver microsomal enzyme systems
28. N-oxide reduction by haemoglobin, cytochrome c and ferrous ions
29. Involvement of liver aldehyde oxidase in the reduction of nicotinamide N-oxide
30. NAD(P)H-dependent reduction of nicotinamide N-oxide by a unique enzyme system consisting of liver microsomal NADPH-cytochrome c reductase and cytosolic aldehyde oxidase
31. Properties of a N,N-dimethyl-paminoazobenzene oxide reductase purified from rat liver cytosol
32. Reduction of tertiary amine N-oxides by liver microsomal P-450
33. The enzymatic reduction of nicotinamide N-oxide
34. The reduction of nicotinamide N-oxide by xanthine oxidase
35. Catalysis of the direct transfer of oxygen from nicotinamide N-oxide to xanthine by xanthine oxidase
36. Reduction in vivo of (-)-nicotine-1′-N-oxide by germ free and conventional rats
37. Pyridine nucleotide cofactor requirements of indicine N-oxide reduction by hepatic microsomal cytochrome P-450
38. Reduced nicotinamide adenine dinucleotide-dependent reduction of tertiary amine N-oxide by liver microsomal cytochrome P450
39. Reduction of tertiary amine N-oxides by cytochrome P-450. Mechanism of the stimulatory effect of flavins and methyl viologen
40. III Nitrogenous compounds as ligands to haemoporphyrins- The concept of metabolic intermediary complexes
41. Mechanism of cytochrome P-450 catalysis. Mechanism of N-dealkylation and amine oxide deoxygenation
42. Chemical studies on drug metabolism 6. Deoxygenation of tertiary amine N-oxides and arene oxides by iron (II) porphyrin as a model of cytochrome P-450-dependent reduction
43. Iron-EDTA stimulated reduction of indicrine N-oxide by the hepatic microsomal fraction, isolated hepatocytes, and the intact rat
44. The interaction of aminoalkylaminoanthraquinones with deoxyribonucleic acid
45. Evaluation of the binding of some substituted anthraquinones and naphthacenequinones to DNA
46. Antitumor agents. 1. 1,4-bis[(aminoalkyl)amino]-9,10-anthracenediones
47. Comparison of antineoplastic activity of aminoethylaminoanthraquinones and anthracycline antibiotics
48. Experimental antitumour activity of aminoanthraquinones
49. Interactions of the antitumour agents mitoxantrone and bisantrene with deoxyribonucleic acids studied by electron microscopy
50. Characteristics of the binding of the anticancer agents mitoxantrone and ametantrone and related structures to deoxyribonucleic acids
51. Comparative computer graphics and solution studies of the DNA interaction of substituted anthraquinones base on doxorubicin and mitoxantrone
52. A theoretical investigation on the sequence-selective binding of mitoxantrone to double stranded DNA
53. High field1NMR analysis of the 1:1 intercalation complex of the antitumour agent mitoxantrone and the DNA duplex [d(CpGpCpGp)]2
54. Kinetics of binding of mitoxantrone, ametantrone and analogues to DNA: relationship with binding mode and anti-tumor activity
55. DNA sequence preferences for the anticancer drug mitoxantrone and related anthraquinones revealed by DNAase I footprinting
56. Interactions of a new antitumor agent, 1,4-dihydroxy-5,8-bis[[2-[2-hydroxyethyl)amino]-ethyl]amino]-9-10-anthracenedione, with nucleic acids
57. Dissociation kinetics of DNA-anthracycline and DNA-anthraquinone complexes determined by stop flow spectrophotometry
58. Stopped-flow kinetic analysis of the interaction of anthraquinone anticancer drugs with cald thymus DNA, poly[d(G-C)]poly[d(G-C)] and poly[d(A-T)]poly[d(A-T)]
59. Conformational flexibility of dinucleotide dimers unwinding from the B-form to an intercalation structure
60. Experimental therapeutic and biochemical studies of anthracenedione derivatives
61. Action of dihydroxyanthraquinone on cell cycle progression of a variety of cultured mammalian cells
62. DNA-binding specificity and RNA polymerase inhibitory activity of bis(aminoalkyl)anthraquinones and bis(methylthio)vinylquinolinium iodides
63. Relationship between the pharmacological activity of ametantrone and mitoxantrone and their ability to condense nucleic acids
64. Protein associated DNA single strand breaks and cytotoxicity of dihydroxyanthracenedione (DHAD)NSC 301739 in mouse 1210 leukaemia cells
65. Comparative molecular pharmacology in leukemic L1210 cells of the anthracene anticancer drugs mitoxantrone and bisantrene
66. Adriamycin induced DNA damage mediated by DNA topoisomerase II
67. Mitoxantrone affects topoisomerase activities in human breast cancer cells
68. DNA topoisomerase poisons as antitumour drugs
69. DNA topoisomerase dysfunction: A new goal for antitumour chemotherapy
70. Catalytic function of DNA topoisomerase II
71. Persistent intracellular binding of mitoxantrone in a human colon carcinoma cell line
72. Cytogenetic and phenotypic analysis of a human colon carcinoma cell line resistant to mitoxantrone
73. Mitoxantrone-DNA binding and the induction of topoisomerase II associated DNA damage in multi-drug resistant small cell lung cancer cells
74. Long-term trapping of DNA synthesis and the persistence of trapped topoisomerase II complexes in determining the toxicity of the antitumour DNA intercalators mAMSA and mitoxantrone
75. Subcellular distribution of the anticancer drug mitoxantrone in human and drug-resistant murine cells analyzed by flow cytotometry and confocal microscopy and its relationship to the induction of DNA damage
76. Evidence for impaired mitoxantrone and vinblastine binding in P388 murine leukaemia cells with multidrug resistance
77. Bis(alkylamino)anthracenedione antineoplastic agent metabolic activation by NADPH-cytochrome P450 reductase and NADH dehydrogenase
78. The biochemical basis of anthracycline toxicity
79. Involvement of hydroxyl radical formation and DNA strand breakage in the cytotoxicity of anthraquinone antitumour agents
80. Differential oxygen radical susceptibility of adriamycin-sensitive and adriamycin-resistant MCF-7 human breast cancer cells: implications for the mechanism of action
81. Lack of involvement of reactive oxygen in the cytotoxicity of mitoxantrone, CI941 and ametantrone in MCF-7 cells: comparison with doxorubicin
82. NAD(P)H (quinone acceptor) oxidoreductase (DT-diaphorase) mediated two electron reduction of anthraquinonebased antitumour agents and generation of hydroxyl radicals
83. Horseradish peroxidase-catalysed oxidation of mitoxantrone: spectrophotometric and electron paramagnetic studies
84. Interaction of the peroxidase-derived metabolite of mitoxantrone with nucleic acids: evidence for covalent binding of14C-labelled drug
85. DNA strand breakage by peroxidase-activated mitoxantrone J
86. Synthesis and antineoplastic activity of 1,4-Bis(aminoalkanamido)9,10-anthracenediones
87. Structure-activity relationship study of anthraquinones: 1,4-dihydroxy-5,8-bis[[2-(2-hydroxyethoxy)ethyl]amino]-9,10-anthracenedione, an analog of an established antineoplastic agent
88. N-oxides of DNA affinic agents as bioreductively activated prodrugs
89. Anthraquinone anticancer compounds with (disubstituted amino-N-oxide)alkylamino substituent